Brief: Lixte Biotechnology Announces Approval Of A Phase 1B/2 Randomized Trial Of Doxorubicin +/-Lb-100 In Advanced Soft Tissue Sarcomas To Be Conducted By The Spanish Sarcoma Group

NOMAD Power Solutions

13/10/2022 13:38

Oct 13 (Reuters) - Lixte Biotechnology Holdings Inc
 LIXT.O :
    * LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2
RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT
TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

Source text for Eikon:  ID:nGNXb4qGhl 
Further company coverage:  LIXT.O 
 ((Reuters.Briefs@thomsonreuters.com;))